Proteomics scores gold standard lab approval in US

The company’s PromarkerEndo for detecting endometriosis and other tests in development will also benefit from the advanced features of the new spectrometry platform.

Dr Richard Lipscombe, managing director of Proteomics International Laboratories, said:: “Our company continues to raise its international profile with these achievements. Achieving CLIA/CAP certification is another important milestone in the commercialization of the Promarker diagnostic suite. CAP is a universally recognized clinical accreditation that puts Proteomics International on the map as a leading provider of quality precision diagnostics.”

CAP accreditation involves a comprehensive review of laboratory records, quality control procedures, personnel qualifications, equipment, facilities, safety programs and general management.

The process ensures compliance with the highest standards of care, reduces risk and supports improved patient outcomes.

The company says these developments will significantly strengthen Proteomics International’s position in delivering innovative predictive and prognostic diagnostics in the world’s largest healthcare market.

With CAP accreditation secured along with cutting-edge spectrometry capabilities, Proteomics International is strongly positioned to accelerate commercialization of the Promarker precision diagnostic pipeline in the United States.

The launch of PromarkerEso in 2026 represents another milestone on the comprehensive path to transforming early detection and patient outcomes in esophageal cancer and beyond.

Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au